Direct and indirect interactions between antidepressant drugs and CYP2C6 in the rat liver during long-term treatment

European Neuropsychopharmacology

Volumn 16, Issue 8, 2006, Pages 580-587

  Daniel, W A ^a   Haduch, A ^a   Syrek, M ^a   Boksa, J ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

CYP2C6; Fluoxetine; Liver; Mirtazapine; Nefazodone; Rat; Sertraline; Tricyclic antidepressants

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CYTOCHROME P450 2C6; DESIPRAMINE; ENZYME; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; SERTRALINE; UNCLASSIFIED DRUG; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; HYDROXYLATION; LIVER MICROSOME; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REACTION ANALYSIS; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTICOAGULANTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BLOTTING, WESTERN; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; LIVER; MALE; MICROSOMES, LIVER; RATS; RATS, WISTAR; STEROID 21-HYDROXYLASE; TIME FACTORS; WARFARIN;

EID: 33750807067     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2006.01.004     Document Type: Article

References (48)

1. Baldwin S.J., Bloomer J.C., Smith G.J., Ayrton A.D., Clarke S.E., and Chenery R.I. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25 (1995) 261-270
2. Barbhaiya R.H., Buch A.B., and Greene D.S. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br. J. Pharmacol. 42 (1996) 573-581
3. Bensoussan C., Delaforge M., and Mansuy D. Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem. Pharmacol. 49 (1995) 591-602
4. Breyer U. Accumulation and elimination of a novel metabolite during chronic administration of the phenothiazine drug perazine to rats. Biochem. Pharmacol. 21 (1972) 1419-1429
5. Cresteil T., Celier C., Kremers P., Flinois J.P., Beaune Ph., and Leroux J.P. Induction of drug metabolizing enzymes by tricyclic antidepressants in human liver: characterization and partial resolution of cytochrome P-450. Br. J. Clin. Pharmacol. 1 (1983) 651-657
6. Daniel W.A., and Melzacka M. The effect of antidepressants on ethylmorphine and imipramine N-demethylation in rat liver microsomes. J. Pharm. Pharmacol. 38 (1896) 396-398
7. Daniel W., and Netter K.J. Alteration of cytochrome P-450 by prolonged administration of imipramine and/or lithium to rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 342 (1990) 234-240
8. Daniel W., Friebertshäuser J., and Steffen C. The effects of imipramine and desipramine on mixed function oxidase in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 328 (1984) 83-86
9. Daniel W.A., Syrek M., Haduch A., and Wójcikowski J. The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. Exp. Toxic. Pathol. 51 (1999) 309-314
10. Daniel W.A., Syrek M., Haduch A., and Wójcikowski J. Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants. Br. J. Pharmacol. 131 (2000) 287-295
11. Daniel W.A., Syrek M., Haduch A., and Wójcikowski J. The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat. J. Pharm. Pharmacol. 53 (2001) 449-461
12. Daniel W.A., Haduch A., and Wójcikowski J. Inhibition and possible induction of rat CYP2D after short- and long-term treatment with antidepressants. J. Pharm. Pharmacol. 54 (2002) 1545-1552
13. Eagling V.A., Tja I.F., and Back D.J. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br. J. Clin. Pharmacol. 45 (1998) 107-114
14. Engel G., Hofmann U., Heidemann H., Cosme J., and Eichelbaum M. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine,3-hydroxymethylantipyrine, and norantipyrine formation. Clin. Pharmacol. Ther. 59 (1996) 613-623
15. Fasco M.J., Silkworth J.B., Dunbar D.A., and Kaminsky L.S. Rat small intestinal cytochromes P450 probed by warfarin metabolism. Mol. Pharmacol. 43 (1993) 226-233
16. Gerbal-Chaolin S., Pascussi J.-M., Pichard-Garcia L., Daujat M., Waechter F., Fabre J.-M., Carrére N., and Maurel P. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab. Dispos. 29 (2001) 242-251
17. Gottlieb R.A., Huang C., Paromov V., Taukada Y., and Wentworth P. Role of cytochrome P450 in myocardial reperfusion injury. Cardiovasc. J. South. Afr. 4 Suppl 1 (2004) S1
18. Haduch, A., Wójcikowski, J., Daniel, W.A., (in press). The effect of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) and newer antidepressant drugs on the activity and level of rat CYP3A. Eur. Neuropsychopharmacol.
19. He K.J., Ejiri N., Nakajama H., and Doi K. Effects of pregnancy on CYPs protein expression in rat liver. Exp. Mol. Pathol. 78 (2005) 64-70
20. Hemeryck A., De Vriendt C., and Belpaire F.M. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. Eur. J. Clin. Pharmacol. 54 (1999) 947-951
21. Hermodson M.A., Barker W.M., and Link K.P. Studies on the 4-hydroxycoumarins. Synthesis of the metabolites and some other derivatives of warfarin. J. Med. Chem. 14 (1971) 167-169
22. Honkakoski P., and Negishi M. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem. J. 347 (2000) 321-337
23. Kaminsky L.S., and Zhang Z.Y. Human P450 metabolism of warfarin. Pharmacol. Ther. 73 (1997) 67-74
24. Kobayashi K., Urashima K., Shimada N., and Chiba K. Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochem. Pharmacol. 63 (2002) 889-896
25. Kobayashi K., Urashima K., Shimada N., and Chiba K. Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: Study with cDNA-expressed systems of the rat. Drug Metab. Dispos. 31 (2003) 833-836
26. Lang D., and Bocker R. Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxywarfarin, a marker for human cytochrome P-4502C9 activity. J. Chromatogr., B, Biomed. Sci. Appl. 672 (1995) 305-309
27. Lewis D.F.V. Guide to cytochromes P450. Structure and Function (2001), Taylor and Francis, London 83
28. Maes M. The immunoregulatory effects of antidepressants. Hum. Psychopharmacol. 16 (2001) 95-103
29. Masubuchi Y., Takahashii C.H., Fujio N., Horie T., Suzuki T., Imaoka S., Funae Y., and Narimatsu S. Inhibition and induction of cytochrome P450 isoenzymes after repetitive administration of imipramine in rats. Drug Metab. Dispos. 23 (1995) 999-1003
30. McNeil C.M., and Murray M. Inhibition of microsomal cytochromes P450 in rat liver by the tricycle antidepressant drug desipramine and its primary oxidized metabolites. Biochem. Pharmacol. 51 (1996) 15-20
31. McSorley L.C., and Daly A.K. Identification of human cytochrome P450 isoforms that contribute to all-trans-retinole acid 4-hydroxylation. Biochem. Pharmacol. 60 (2000) 517-526
32. Murray M., and Field S.L. Inhibition and metabolite complexation of rat hepatic microsomal cytochrome P450 by tricyclic antidepressants. Biochem. Pharmacol. 43 (1992) 2065-2071
33. Murray M., and Murray K. Mechanism-based inhibition of CYP activities in rat liver by fluoxetine and structurally similar alkylamines. Xenobiotica 33 (2003) 973-987
34. Nelson M.H., Birnbaum A.K., and Remmel R.P. Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors. Epilepsy Res. 44 (2001) 71-82
35. O'Malley K., Braunung M., Stevenson I., and Turnbull M.J. Stimulation of drug metabolism in man by tricyclic antidepressants. Eur. J. Clin. Pharmacol. 6 (1973) 102-106
36. Newton D.J., Wang R.W., and Lu A.Y.H. Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23 (1995) 154-158
37. Papp M., Moryl E., and Willner P. Pharmacological validation of the chronic mild stress model of depression. Eur. J. Pharmacol. 296 (1996) 129-136
38. Pascussi J.M., Gerbal-Chaloin S., Drocourt L., Fabre J.M., Maurel P., and Vilarem M.J. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim. Biophys. Acta 1619 (2003) 243-253
39. Pascussi J.M., Gerbal-Chaloin S., Pichard-Garcia L., Daujat M., Fabre J.M., Maurel P., and Vilarem M.J. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem. Biophys. Res. Commun. 274 (2000) 707-713
40. Rifkind A.B., Lee C., Chang T.K.H., and Waxman D.J. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch. Biochem. Biophys. 320 (1995) 380-389
41. Ryan D.E., and Levin W. Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol. Ther. 45 (1990) 153-239
42. Shaw P.M., Adesnik M., Weiss M.C., and Corcos L. The phenobarbital-induced transcriptional activation of cytochrome P-450 genes is blocked by the glucocorticoid-progesterone antagonist RU486. Mol. Pharmacol. 44 (1993) 775-783
43. Shin J.G., Park J.Y., Kim M.J., Shon J.H., Yoon Y.R., Cha I.J., Lee S.S., Oh S.W., Kim S.W., and Flockhart D.A. Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab. Dispos. 30 (2002) 1102-1107
44. Tréluyer J.M., Benech H., Colin I., Pruvost A., Chéron G., and Cresteil T. Ontogenesis of CYP2C-dependent arachidonic acid metabolism in the human liver: Relationship with sudden infant death syndrome. Pediatr. Res. 47 (2000) 677-683
45. Warrington S.J. Clinical implications of the pharmacology of serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. 7 (1992) 13-19
46. Wójcikowski J. Potential role of the brain dopaminergic system in the regulation of cytochrome P-450 expression. Pol. J. Pharmacol. 56 (2004) 701-708
47. Yamazaki H., Komatsu T., Takemoto T., Saeki M., Minami Y., Kawaguchi Y., Shimada N., Nakajima M., and Yokoi T. Decreases in phenytoin hydroxylation activities catalyzed by liver microsomal cytochrome P450 enzymes in phenytoin-treated rats. Drug Metab. Dispos. 29 (2001) 427-434
48. Yamazaki H., and Shimada T. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch. Biochem. Biophys. 346 (1997) 161-169